Antiviral Drugs Market to Reach US$66.79 Billion by 2030 |

Pune, Aug. 10, 2022 (GLOBE NEWSWIRE) — The Global antiviral drugs market it is expected that the clock $66.79 billion by 2030 Due to presence of a well-established supply chain, growing interest in supporting the development of innovative antiviral drugs, and increased public awareness.

market engine

Virus infections like influenza, respiratory syncytial virus, hepatitis, and HIV are the major factors driving the global antiviral drugs market. The expansion of the market is expected to be restrained by an increase in research and development activities and the invention of new formulations like vaccines and alternative therapies.

In 2019, there were 37.9 million people living with HIV/AIDS worldwide, according to a UNAIDS report. Within this, there are 36.2 million adults, 1.7 million children and 770,000 people who have died from this disease.

The availability of a well-established supply chain, growing interest in the development of innovative antiviral drugs, and increased public awareness are all contributing to the rapid expansion of the market.

Request a sample copy of the research report: https://growthplusreports.com/inquiry/request-sample/antiviral-drugs-market/7753

Excerpts from ‘By Application Segmentation’

On the basis of application, the global antiviral drugs market has been segmented:

  • HIV
  • Hepatitis
  • Herpes
  • Flu
  • Others

The industry leader and owner of the largest revenue share was the HIV segment. The market will grow at a faster rate due to the high incidence of HIV infection, high treatment rate, availability of branded drugs and government attempts to increase the treatment rate. For example, the Ending HIV Epidemic (EHE) strategy, which aims to end the HIV epidemic in the United States by 2030, was unveiled by the federal government in 2019. The project aims to reduce HIV infections while increasing the rate of diagnosis and treatment in the United States. United States. Additionally, the availability of potent treatments for HIV infection in the pipeline will support the expansion of the market over the forecast period.

The expansion of the market will also be facilitated by the significant presence of industry players engaged in the discovery, development and production of innovative drugs to treat hepatitis infections. Through this strategy, competitors’ market positions have increased as product accessibility and availability increases.

Excerpts from ‘Segmentation by region’

On the basis of regions, the global antiviral drugs market has been segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

The largest revenue share in the global antivirals market was occupied by North America. The presence of major pharmaceutical companies in the United States, the increasing incidence of diseases like HIV and respiratory syncytial virus, and increased government funding for the introduction of safe and effective antiviral drugs in North America are all contributing factors. For example, in June 2021, the American Rescue Plan secured a $3 billion commitment from the US government to accelerate the discovery, development, and production of antiviral drugs. Under the plan, up to US$1.2 billion would be donated to Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern, which will utilize the creativity of the biomedical research community. to promote the discovery and development of new antiviral drugs. This factor is expected to fuel the market revenue growth in this region.

Due to the huge patient population and increasing R&D spending by pharmaceutical companies, the antiviral drug market in Asia-Pacific is growing at the fastest rate in the world. Additionally, public spending on clinical trials and other research initiatives will increase due to increased funding. Remdesivir, an antiviral drug manufactured by Gilead Science, received marketing clearance from the Central Drugs Standard Control Organization (CDSCO) in June 2020 for the treatment of COVID-19 infection in India. Accordingly, the rising demand for effective treatments to treat COVID-19 infection will further fuel the growth of the regional market.

Browse Full Report Information: https://growthplusreports.com/report/antiviral-drugs-market/7753

Excerpts from “Competitive Landscape”

The production and distribution of antiviral drugs is handled by a number of generic pharmaceutical companies, which makes the global market extremely competitive.

Some of the major players operating in the global antiviral drugs market include:

  • Astra Zeneca plc
  • F. Hoffmann-La Roche SA
  • GlaxoSmithKline, Plc
  • Bristol-Myers-Squibb Company
  • Abbott Laboratories Inc.
  • Schering-Plough Company
  • Merck & Co., Inc.
  • Johnson & Johnson Services, Inc.
  • AbbVie Inc
  • Cipla, Inc.
  • Dr Reddy Laboratories Ltd
  • Among others

Report Scope and Segmentation:

Report cover Details
Market size in 2021 $49 billion
Revenue forecasts in 2030 $66.79 billion
Rate of growth CAGR of 3.5% from 2022 to 2030
Base year for the estimate 2021
Forecast period 2022-2030
Segments Covered Drug class, type, application, distribution channel
Regional scope North America, Europe, Asia-Pacific and Rest of the World (ROW)

Contents:

INTRODUCTION

  1. RESEARCH METHODOLOGY
    1. Research approach
    2. Data collection methodology
    3. Information source
      1. Secondary sources
      2. Primary sources
    4. Market estimation approach
      1. From bottom to top
      2. From top to bottom
    5. Market Forecast Model
    6. Limits and assumptions
  2. PREMIUM OVERVIEW
    1. Current market trend (COVID-19 outlook)
    2. Key players and competitive positioning (2021)
  3. MARKET DYNAMICS
    1. Drivers
    2. Constraints
    3. Opportunities
    1. Market ecosystem
    2. Schedule under study
      1. Historical years – 2020
      2. Base year – 2021
      3. Planned years – 2022 to 2030
    3. Currency used in the report

Knock Continued..

Request customization of this research report to: https://growthplusreports.com/inquiry/customization/antiviral-drugs-market/7753

About Us:

Growth+Reports is part of GRG Health, a global healthcare knowledge services company. We are proud members of the EPhMRA (European Pharmaceutical Marketing Research Association).

The Growth+ portfolio of services leverages our core capabilities in secondary and primary research, market modeling and forecasting, benchmarking, analysis and strategy formulation to help clients create scalable and game-changing solutions. that prepare them for future growth and success.

We have been recognized by the prestigious CEO Magazine as “2020’s Most Innovative Healthcare Market Research Company”.


        

Comments are closed.